These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 136763)

  • 61. The pathophysiology and pathoanatomy of reactions to antimicrobial agents.
    Weinstein L; Weinstein AJ
    Adv Intern Med; 1974; 19():109-34. PubMed ID: 4273657
    [No Abstract]   [Full Text] [Related]  

  • 62. Allopurinol sensitivity: report of two cases.
    Haughey DB; Lanse S; Imhoff T; Tobin M; Schentag JJ
    Am J Hosp Pharm; 1979 Oct; 36(10):1377-80. PubMed ID: 159623
    [No Abstract]   [Full Text] [Related]  

  • 63. Withdrawal of oxyphenbutazone: what about phenylbutazone?
    Biron P
    CMAJ; 1986 May; 134(10):1119-20. PubMed ID: 3697857
    [No Abstract]   [Full Text] [Related]  

  • 64. [Gastro-duodenal tolerance of some drugs with analgesic effect. Clinico-endoscopic considerations].
    Fichera G; Mirelli E
    Minerva Med; 1974 Feb; 65(14):768-77. PubMed ID: 4545237
    [No Abstract]   [Full Text] [Related]  

  • 65. [Chloramphenicol, after 30 years].
    Toma E
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(6):495-501. PubMed ID: 44751
    [No Abstract]   [Full Text] [Related]  

  • 66. Phenylbutazone overdosage: abnormal metabolism associated with hepatic and renal damage.
    Prescott LF; Critchley JA; Balali-Mood M
    Br Med J; 1980 Oct; 281(6248):1106-7. PubMed ID: 7427601
    [No Abstract]   [Full Text] [Related]  

  • 67. Phenylbutazone, oxyphenbutazone labeling revised.
    FDA Drug Bull; 1984 Dec; 14(3):23-4. PubMed ID: 6526172
    [No Abstract]   [Full Text] [Related]  

  • 68. Primary fibrositis and its treatment with the pyrazolone derivatives, butazolidin and tandearil.
    Klinefelter HF
    Johns Hopkins Med J; 1972 May; 130(5):300-7. PubMed ID: 4259693
    [No Abstract]   [Full Text] [Related]  

  • 69. Fixed drug eruption to oxyphenbutazone and phenylbutazone.
    Nayyar KC; Pasricha JS
    Dermatologica; 1972; 144(4):214-6. PubMed ID: 5076722
    [No Abstract]   [Full Text] [Related]  

  • 70. Side-effects of non-steroidal anti-inflammatory drugs.
    Brooks PM
    Med J Aust; 1988 Mar; 148(5):248-51. PubMed ID: 2963948
    [No Abstract]   [Full Text] [Related]  

  • 71. Letter: Fixed skin eruption caused by oxyphenbutazone with cross-reactivity to phenylbutazone.
    Pandhi RK; Dedi TR
    Arch Dermatol; 1975 Jan; 111(1):131. PubMed ID: 1119818
    [No Abstract]   [Full Text] [Related]  

  • 72. [Hematologic diseases caused by drugs (proceedings)].
    MMW Munch Med Wochenschr; 1979 May; 121(21):714-5. PubMed ID: 111060
    [No Abstract]   [Full Text] [Related]  

  • 73. Adverse effects of corticosteroids: II. Systemic.
    Davis GF
    Clin Dermatol; 1986; 4(1):161-9. PubMed ID: 2978681
    [No Abstract]   [Full Text] [Related]  

  • 74. Side effects of ibuprofen.
    Sternlieb P; Robinson RM
    Ann Intern Med; 1980 Apr; 92(4):570. PubMed ID: 6444790
    [No Abstract]   [Full Text] [Related]  

  • 75. Monitoring of nonsteroidal antiinflammatory drugs.
    Cervini C; Grassi W
    Int J Clin Pharmacol Res; 1985; 5(4):273-7. PubMed ID: 2932400
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phenylbutazone and oxyphenbutazone: time to call a halt.
    Drug Ther Bull; 1984 Jan; 22(2):5-6. PubMed ID: 6692755
    [No Abstract]   [Full Text] [Related]  

  • 77. [Adverse effects of chemical mediator release inhibitors].
    Onoda M; Inokuma S; Ikezawa Z
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():259-66. PubMed ID: 18074547
    [No Abstract]   [Full Text] [Related]  

  • 78. Generalized pustular psoriasis precipitated by phenylbutazone and oxyphenbutazone.
    Reshad H; Hargreaves GK; Vickers CF
    Br J Dermatol; 1983 Jul; 109(1):111-3. PubMed ID: 6860567
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Unwanted side effects of bêta-blockers (author's transl)].
    Hugues FC; Penso D; Marche J
    Therapie; 1980; 35(2):155-71. PubMed ID: 6106306
    [No Abstract]   [Full Text] [Related]  

  • 80. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.
    Ibraheim H; Perucha E; Powell N
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii17-vii28. PubMed ID: 31816081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.